Registration Number
0221U100446,
0119U103007
, R & D reports
Title
Determine the role of cyclooxygenase-2 inhibitors in combination with cytostatics in radiomodification of radiation therapy for non-small cell lung and squamous cell carcinoma of the head and neck
popup.stage_title
Head
Mitryaeva Nataliya A., Доктор біологічних наук
Starenkiy Viktor P., Доктор медичних наук
Registration Date
05-01-2021
Organization
State Organization "Grigoriev Institute for Medical Radiologiy of the National Academy of Medical Sciences of Ukraine"
popup.description2
The object of study: the effectiveness of radiation therapy in combination with a cyclooxygenase-2 inhibitor - ranselex and cisplatin in patients with non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (PRGS) with the content of angiogenesis inhibitors PEG-2 and VEGF 2 in blood serum. The aim of the work: is to increase the effectiveness of radiation therapy of non-small cell lung cancer and squamous cell carcinoma of the head and neck by radiomodification with cyclooxygenase-2 inhibitors (celecoxibs) in combination with cytostatics (cisplatin) based on determining the mechanisms of their radiosensitizing action. Methods of research and equipment: clinical and instrumental, immunoassay, dosimetric, statistical; the immunoenzymometric analyzer Immunochem-2100, the universal dosimeter UNIDOS_E, the linear accelerator Clinac-600. Theoretical and practical results: it is established that the frequency of regressions during irradiation on a linear accelerator in the mode of classical fractionation in combination with COX-2 inhibitor and cisplatin in patients with GDR increases by 13.3%, reaches 83.3%, due to the number partial regressions, in patients with PRGS - 40% due to complete regressions. A comparative analysis of VEGF changes in radiation therapy (PT) showed that a more pronounced decrease in VEGF was observed after PT in combination with cisplatin and COX-2 inhibitor-ranselex than in PT in combination with ranselex alone, which increases inhibition of angiogenesis. Novelty: for the first time, scientific data were obtained on the mechanisms of radiation therapy in combination with COX-2 inhibitor - rancelex and cisplatin on the content of proangiogenic factor VEGF and inducers of angiogenesis COX-2 and PGE-2 in the serum of patients with NDRL and PRGS. Implementation efficiency: improving the effectiveness of treatment. Domain of usage: radiation oncology.
Product Description
popup.authors
Artiukh Serhii V.
Bilozor Nataliya V.
Grebinyk Lidiya V.
Kantsedal Olena M.
Kolomatska Viktoriia V.
Kondrashova Olena I.
Kurov Oleksandr M.
Lukashkova Olha P.
Makaruk Olena V.
Maslennikova Olena L.
Potapova Tatyana I
Pshyshevska Ludmila M.
Teslenko Irina M.
Tkathenko Alla A.
Uzlenkova Nataliya Ye.
popup.nrat_date
2021-01-05
